New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
20:25 EDTCOCO, COCO, NS, NS, LII, LII, BIP, BIP, NDAQ, NDAQ, LVLT, LVLT, GRA, GRA, CCE, CCE, BEAM, BEAM, RL, RL, MMP, MMP, HUM, HUM, EL, EL, CTSH, CTSH, AGN, AGN, ADP, ADP, TWX, TWX, MRK, MRKNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Merck (MRK), consensus 88c; Time Warner (TWX), consensus $1.15; Automatic Data Processing (ADP), consensus 77c; Allergan (AGN), consensus $1.34; Cognizant (CTSH), consensus $1.06; Estee Lauder (EL), consensus $1.06; Humana (HUM), consensus 94c; Magellan Midstream (MMP), consensus 81c; Ralph Lauren (RL), consensus $2.51; Beam (BEAM), consensus 72c; Coca-Cola Enterprises (CCE), consensus 52c; W.R. Grace (GRA), consensus $1.19; Level 3 (LVLT), consensus 3c; Nasdaq (NDAQ), consensus 67c; Brookfield Infrastructure Partners (BIP), consensus 35c; Lazard (LAZ), consensus 61c; Arrow Electronics(ARW), consensus $1.62; Lennox International (LII), consensus 74c; NuStar Energy (NS), consensus 35c; Corinthian Colleges (COCO), consensus 2c.
News For MRK;TWX;ADP;AGN;CTSH;EL;HUM;MMP;RL;BEAM;CCE;GRA;LVLT;NDAQ;BIP;LII;NS;COCO From The Last 14 Days
Check below for free stories on MRK;TWX;ADP;AGN;CTSH;EL;HUM;MMP;RL;BEAM;CCE;GRA;LVLT;NDAQ;BIP;LII;NS;COCO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
July 15, 2014
09:59 EDTCOCOApollo Education discloses new Department of Education review
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
07:24 EDTLVLTMicrosoft to hold a conference
MSFT Worldwide Partner Conference to be held in Washington, D.C. on July 13-17.
06:43 EDTTWXTime Warner looks for NBA programming deal renewal, Bloomberg says
Time Warner (TWC) and Disney's (DIS) ESPN are looking to renew the last big U.S. sports agreement with the National Basketball Association that’s up for grabs until 2021, according Reuters, citing people familiar with the talks. Time Warner and Disney, which divvy-up airing the games, pay the league an average total of $930M annually. Reference Link
06:36 EDTTWXNBA seeks to double TV-rights fees from Disney, Time Warner, WSJ reports
Subscribe for More Information
06:06 EDTTWXTime Warner downgraded to Equal Weight from Overweight at Evercore
Subscribe for More Information
July 14, 2014
16:15 EDTHUMHumana, Tenet sign new multi-year national agreement
Subscribe for More Information
12:47 EDTAGNAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
10:00 EDTNDAQOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:01 EDTELMovado names Ricardo Quintero as president, effective today
Subscribe for More Information
08:13 EDTAGNAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTAGNValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
07:22 EDTHUMHealthcare Education Associates to hold a conference
4th Annual RISE California Summit to be held in San Diego on July 13-15.
06:42 EDTTWX'Dawn of the Planet of the Apes' leads box office with $73M opening, WSJ says
Subscribe for More Information
06:13 EDTNDAQNASDAQ upgraded to Overweight from Equal-Weight at Evercore
Subscribe for More Information
July 11, 2014
16:48 EDTAGNAllergan comments on Pershing Square’s definitive proxy solicitation
Allergan (AGN) provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management in connection with Pershing Square’s request to call a Special Meeting of Stockholders. At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals' (VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer. Under the current Board’s leadership, which includes individuals with significantly more industry experience than Pershing Square’s recommended nominees, Allergan continues to execute on its plan to drive near- and long-term organic growth, enhance its growth prospects and continue generating significant value for all of Allergan’s stockholders. We believe Pershing Square’s attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price that substantially undervalues the company and creates significant risks and uncertainties for Allergan stockholders. Valeant has repeatedly failed to address the serious concerns raised by Allergan and important members of the investment community about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues. Allergan has a track record of consistently acting in the best interests of its stockholders and the Board remains confident in the company’s ability to create significantly more value than Valeant’s proposal.
11:54 EDTAGNAbbVie, Shire in active takeover talks, Bloomberg reports
AbbVie (ABBV) and Shire (SHPG) are in active talks about a potential merger after AbbVie raised its takeover offer for a fourth time, Bloomberg reports, citing people with knowledge of the matter. The talks are in the early stage and may not lead to an agreement, sources told Bloomberg. Shares of Shire are up 5%, or $12.04, to $250.65 following the report.
11:17 EDTCCEHigh option volume stocks
Subscribe for More Information
08:36 EDTNDAQNASDAQ Hearings Panel approves continued listing of Ixia shares
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use